Abstract 15273: Baroreflex Activation Therapy Significantly Lowers NTproBNP in Patients with Symptomatic Heart Failure
Background: Baroreflex activation therapy (BAT) modulates sympathovagal balance, which is impaired in patients with heart failure leading to increased morbidity and mortality. Our aim was to study the effect of BAT on levels of the prognostic marker NTproBNP, NYHA class and 6-Minute-Walk-Test in patients with heart failure and reduced ejection fraction.
Methods: 5 Patients were implanted with the CVRx neoTM system (CVRx Inc., Minneapolis, Minnesota) at the University of Cologne as part of a first-in-man study of BAT for systolic heart failure. They had an ejection fraction of <35% (mean 27.8±2.8%), and were in NYHA class III before BAT (inclusion criteria). NTproBNP measurements were repeatedly performed prior to implant and during follow-up. NTproBNP was quantified as the average of all available values before and on BAT. All data are presented as mean±SEM.
Results: NTproBNP decreased in all patients on BAT. NTproBNP was 3184±1000 ng/l prior to BAT and fell to 1516±291 ng/l during an average follow-up of 4.2 months, reflecting an individual decline of 47±7% (p<0.05). NYHA class decreased from 3.0±0.0 to 2.6±0.2 (p=0.09). 6-Minute-Walk-Test improved from 356.7±14.5 m to 408.3±8.3 m (p<0.05). Body mass index and heart failure medications were stable.
Conclusions: These preliminary, first-in-man data indicate that BAT significantly lowers levels of NTproBNP in patients with systolic heart failure and improves 6-Minute-Walk-Test and NYHA functional class at least in trend. These findings suggest that BAT may improve clinical status and possibly prognosis in heart failure patients. These promising initial results encourage pursuing the study of BAT in patients with heart failure.
- © 2012 by American Heart Association, Inc.